Understanding MVID

Explore this site to learn about MVID, patient resources, our research and future work towards a new therapy.

What is MVID

New research and comprehensive resources for patients with microvillus inclusion disease

Microvillus inclusion disease (MVID) is a rare, genetic disease that causes chronic diarrhea in young babies. The amount of diarrhea often exceeds that of cholera, and infants will die unless they are given appropriate and often massive amounts of intravenous fluid. Patients with MVID often survive solely on IV fluids, also known as total parenteral nutrition or TPN, or they must undergo a small bowel transplant. Learn more about MVID.

At Vanessa Research we have patented and will soon begin clinical trials of a drug that has been developed to treat MVID – a treatment that will eliminate life-threatening diarrhea by encouraging immature cells in the intestine to grow normally and restore the absorption of fluids and nutrients. Learn more about our research.

New White Paper available now

Addressing the Microvillus Inclusion Disease Knowledge Gap

A Comprehensive Case Analysis Read more

Learn more about
our research.

January 17, 2020 - Hamden, Connecticut
Vanessa Research Interviews with Pharma Boardroom to Highlight their Expansion into the Pharmaceutical Manufacturing Realm

Vanessa Research shares their organizational growth and strategic objectives with healthcare professionals worldwide BUDAPEST, January 16, 2020 — Vanessa Research, (VR) — a biomedical company transforming the healthcare landscape by developing and commercializing innovative products in areas of unmet medical needs— participated in an interview with Pharma Boardroom, the premier website for C-Level executives, consultants,…

Read more
October 9, 2019 - Hamden, Connecticut
Vanessa Research Acquires Hungaro-Gal, Pharmaceutical Manufacturing Plant, for the Production of Investigational Treatment

Vanessa Research (VR) —a biomedical company committed to improving patient quality of life by developing innovative products and solutions in areas of unmet medical needs—has acquired Hungaro-Gal, a Hungarian pharmaceutical contract manufacturing company. Per the acquisition, VR will continue Hungaro-Gal’s contract manufacturing services and intends to maintain and grow their existing customer base. Additionally, VR…

Read more
June 4, 2019 - Hamden, Connecticut
Vanessa Research Gains Approval to Conduct Phase II Clinical Trial for Treatment of Rare Pediatric Disease

Study will evaluate safety and efficacy of Shylicine®, the first-ever investigational treatment developed for microvillus inclusion disease Vanessa Research — a biomedical company founded on the desire to “give hope where none existed” by making an impact on healthcare markets that are often overlooked — has been granted regulatory approval by the Turkish Ministry of…

Read more